

Showcasing research from Chung-Hang Leung's laboratory, University of Macau, Macau.

An iridium(III)-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent

Ma, Cai, Wang, Leung and co-workers have developed the first metal-based inhibitor of the epigenetic target BRD4. The iridium(III) complex inhibited the BRD4-acetylated histone protein–protein interaction *in vitro*, and exhibited potent anticancer activity in an *in vivo* model of melanoma.

As featured in:

See Dik-Lung Ma, Zongwei Cai, Hui-Min David Wang, Chung-Hang Leung *et al.*, *Chem. Sci.*, 2015, **6**, 5400.

ROYAL SOCIETY OF CHEMISTRY

www.rsc.org/chemicalscience

Registered charity number: 207890